Clinical Scorecard: Comparison of Adjuvanted and High-Dose Influenza Vaccines in Older Adults in the United States: A Cluster Randomized Crossover Investigation
At a Glance
Category
Detail
Condition
Influenza in adults aged 65 years or older
Key Mechanisms
Adjuvanted and high-dose vaccines elicit improved immune response compared to standard-dose vaccines.
Target Population
Adults aged 65 years or older
Care Setting
Outpatient settings within an integrated health care delivery system
Key Highlights
Influenza affects 9.4 million to 41 million individuals annually, with a significant burden on older adults.
70% to 85% of influenza-related deaths occur in adults aged 65 years or older.
ACIP recommends adjuvanted or higher-dose vaccines for older adults to improve protection.
Study compares the relative vaccine effectiveness of adjuvanted vs high-dose influenza vaccines.
Cluster randomized crossover design used to ensure balanced vaccine availability across facilities.
Guideline-Based Recommendations
Diagnosis
Use PCR testing for laboratory-confirmed influenza diagnosis.
Management
Administer adjuvanted or high-dose influenza vaccines to adults aged 65 years or older.
Monitoring & Follow-up
Monitor for incident PCR-confirmed influenza 14 days post-vaccination.
Risks
Increased risk of complications from influenza in older adults.
Patient & Prescribing Data
Kaiser Permanente Northern California members aged 65 years or older.
Adjuvanted and high-dose vaccines show comparable effectiveness against influenza-related medical encounters.
Clinical Best Practices
Encourage vaccination in older adults during the influenza season.
Utilize comprehensive electronic medical records for tracking vaccination and outcomes.
Implement cluster randomized designs to evaluate vaccine effectiveness in real-world settings.
by Amber Hsiao, Thomas Leong, Bruce Fireman, John Hansen, Ousseny Zerbo, Karen B. Jacobson, Lauren D. Liao, Mendel D. M. Haag, Ian McGovern, Bin Zhang, Juliet Dang, Nicola P. Klein
